Rune Labs

Rune Labs is a software and data analytics company specializing in precision neurology, founded in October 2018 in San Francisco. The company develops technology platforms that support both clinical care delivery and therapy development for neurodegenerative diseases, with a primary focus on Parkinson's disease through its StrivePD ecosystem.

The company's core offering combines real-world data collection, clinical trial support, and care management tools. StrivePD received FDA 510(k) clearance in June 2022 for monitoring Parkinson's symptoms via Apple Watch. Rune Labs serves two primary customer segments: clinicians and patients through care delivery tools, and life sciences companies through clinical trial platforms (StriveStudy), real-world evidence generation, and commercial channel support. The platform aggregates patient data from multiple sources including wearables, providing clinicians with curated dashboards for personalized symptom tracking and data-enriched care workflows.

Rune Labs has secured approximately $40 million in funding across seed ($5M in 2020), Series A ($22.8M in 2021), and strategic rounds ($12M in 2024). The company has demonstrated clinical impact through partnerships like Kaiser Permanente, where their program nearly halved emergency room visits for Parkinson's patients. Beyond Parkinson's, Rune Labs is expanding into Multiple Sclerosis, OCD, and Essential Tremor research.

Organizations should consider Rune Labs when they need proven expertise in Parkinson's disease management combined with regulatory-cleared technology for remote patient monitoring. The company excels in scenarios requiring integration of wearable data with clinical workflows, clinical trial recruitment and data collection for neurology studies, or generation of real-world evidence for neurodegenerative therapies.

Engagements typically involve implementing their StrivePD care delivery ecosystem for patient management, utilizing their StriveStudy platform for clinical trial support, or accessing their real-world data network for evidence generation. The company's patient-centric approach and emphasis on data privacy and ethics make them suitable for organizations prioritizing compliance and patient trust in precision medicine initiatives.

Rune Labs operates exclusively in healthcare with a specialized focus on neurodegenerative diseases, particularly Parkinson's disease. The company has achieved FDA 510(k) clearance for its StrivePD platform, demonstrating compliance with medical device regulations. Their work emphasizes HIPAA compliance and patient data privacy through purposefully designed legal agreements that prevent misuse of patient data.

The company serves multiple healthcare verticals including health systems (Kaiser Permanente), pharmaceutical companies (BlueRock Therapeutics), academic medical centers (UCSF, Mount Sinai), and clinical research organizations. Their healthcare-specific expertise includes clinical trial support, real-world evidence generation for regulatory submissions, advanced therapy workflows (including deep brain stimulation), and integration with clinical care delivery systems.

The ideal client is a health system with an established neurology or movement disorder program seeking to improve Parkinson's care delivery, or a pharmaceutical/biotech company developing therapies for neurodegenerative diseases that needs clinical trial infrastructure and real-world evidence capabilities. Organizations benefit most when they value precision medicine approaches, have patient populations suitable for remote monitoring, and seek to leverage longitudinal data for improving outcomes or accelerating therapy development.